GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Citius Pharmaceuticals Inc (NAS:CTXR) » Definitions » 5-Year Yield-on-Cost %

CTXR (Citius Pharmaceuticals) 5-Year Yield-on-Cost % : 0.00 (As of Dec. 12, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Citius Pharmaceuticals 5-Year Yield-on-Cost %?

Citius Pharmaceuticals's yield on cost for the quarter that ended in Jun. 2024 was 0.00.


The historical rank and industry rank for Citius Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:



CTXR's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.54
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Citius Pharmaceuticals's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Citius Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Citius Pharmaceuticals's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Citius Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Citius Pharmaceuticals's 5-Year Yield-on-Cost % falls into.



Citius Pharmaceuticals 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Citius Pharmaceuticals is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Citius Pharmaceuticals  (NAS:CTXR) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Citius Pharmaceuticals 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Citius Pharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Citius Pharmaceuticals Business Description

Traded in Other Exchanges
Address
11 Commerce Drive, First Floor, Cranford, NJ, USA, 07016
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
Executives
Myron Z Holubiak director, officer: Vice Chairman C/O CITIUS PHARMACEUTICALS, INC., 63 GREAT ROAD, MAYNARD MA 01754
Dennis M Mcgrath director C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Leonard L Mazur director, 10 percent owner, officer: Chief Executive Officer C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Suren G Dutia director C/O CITIUS PHARMACEUTICALS, INC., 63 GREAT ROAD, MAYNARD MA 01754
Carol Webb director 11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD NJ 07016
Eugene Myron Holuka director 11 COMMERCE DRIVE, 11TH FLOOR, CRANFORD NJ 07016
Jaime Bartushak officer: Chief Financial Officer C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Myron Czuczman officer: Chief Medical Officer C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Howard Safir director 11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD NJ 07016
William Kane director 11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD NJ 07016